Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 12 January 2026 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 5 January 2026 up to and including 9 January 2026 a total of 182,115 shares were repurchased on exchange at an average price of € 68.52. During the same period, 219,305 sh...
BE Semiconductor Industries: Exceptional order intake supports strong FY26. Heineken: Back from the Brink. Wolters Kluwer: An acquisition and a new CP & ESG CEO. Staffing sector: US temp volume touch weaker vs November; downward revisions to Oct/Nov; NFP jobs miss expectations. Coverage change
argenx outlined its strategic priorities for 2026 and shared preliminary Vyvgart sales numbers coming in at $ 4.15b for FY25, more or less in line with CSS of $ 4.13b. Looking ahead, 2026 is set to be a catalyst rich year with 4 registrational readouts and we note that argenx provided more specific timeline guidance for each trial, while the earlier stage pipeline progresses with multiple new additions, and a biotech collaboration. We continue to see upside for the stock in 2026 and maintain our...
CEO of Heineken N.V. to step down on 31 May 2026 CEO of Heineken N.V. to step down on 31 May 2026 Amsterdam, 12 January 2026 – Heineken N.V. today announced that CEO and Chairman of the Executive Board Dolf van den Brink has informed the Supervisory Board of his decision to step down from his position on 31 May 2026. After almost six years at the helm of HEINEKEN during which he has guided the Company through turbulent economic and political times, and with the EverGreen Strategy 2030 in place, Dolf has concluded, in consultation with the Supervisory Board, that this is the right time to h...
argenx Highlights 2026 Strategic Priorities Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contr...
Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder focused on the health and wellness segment in California. The transacti...
Voorkennis: Fagron kondigt de afronding van de overname van University Compounding Pharmacy in Noord-Amerika aan Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 12 januari 2026 – 7:00 AM CET Fagron kondigt de afronding van de overname van University Compounding Pharmacy in Noord-Amerika aan Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, kondigt met genoegen de afronding van de overname van University Compounding Pharmacy (UCP), een 503A-farmaceutisch bereider gericht op de gezondheids- en welzijnssector in Californië, aan. De t...
Disclosure of notification received from BNP Paribas Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 09 January 2026 – 5:40 PM CET Disclosure of notification received from BNP Paribas Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from BNP Paribas Asset Management Holding. Notification by BNP Paribas Asset Management Holding On 7 January 2026, Fagron received a notification that the shareholding of BNP Paribas Asset Management Holding, crossed the disclosure threshold of...
Openbaarmaking van kennisgeving ontvangen van BNP Paribas Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 9 januari 2026 – 17u40 CET Openbaarmaking van kennisgeving ontvangen van BNP Paribas Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van BNP Paribas Asset Management Holding. Kennisgeving van BNP Paribas Asset Management Holding Op 7 januari 2026 heeft Fagron een kennisgeving ontvangen dat het aandeelhouderschap van BNP Paribas Asset Managem...
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the argenx...
Fagron announces the completion of Purifarma Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 January 2026 – 7:00 AM CET Fagron announces the completion of Purifarma Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of Purifarma in Brazil, an important milestone in executing our disciplined M&A strategy. The completion of this transaction follows competition clearance by CADE, the Brazilian antitrust authority, last October, and will strengthen Fagron’s scalable, high-quality platform, in line ...
Fagron kondigt de afronding van de overname van Purifarma aan Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 6 januari 2026 – 7:00 AM CET Fagron kondigt de afronding van de overname van Purifarma aan Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, is verheugd om de afronding van de overname van Purifarma in Brazilië aan te kondigen. Een belangrijke mijlpaal in de uitvoering van onze gedisciplineerde M&A-strategie. De afronding van Purifarma volgt op de goedkeuring van CADE, de Braziliaanse mededingingsautoriteit, in oktober vo...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 5 January 2026 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 29 December 2025 up to and including 2 January 2026 a total of 36,210 shares were repurchased on exchange at an average price of € 69.02. During the same period, 5,641 shar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.